ArticleCureus2025
Risk of Proton Pump Inhibitor (PPI)-Induced Galactorrhea: An Uncommon Adverse Effect of a Common Drug.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Syringic acid protects against indomethacin-induced gastric injury via NF-κB and apoptotic pathway modulation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Galactorrhea is a rare and atypical adverse effect associated with the use of proton pump inhibitors (PPIs). They are widely used in the management of acid-related disorders and have been proven to be effective. However, like all pharmacological therapies, PPI use is accompanied by a range of adverse effects. This case report details a 27-year-old female individual with no significant medical history who presented with galactorrhea. Upon further investigation, PPI-induced galactorrhea was confirmed and discontinuation of the medication resulted in the resolution of the condition. Complex interactions between the drug, various enzymes, and receptors have been postulated as potential mechanisms underlying the development of this condition. Chronic kidney disease has also been shown to augment the development of PPI-induced galactorrhea. Further research around the mechanism driving PPI-induced galactorrhea in patients is necessary to better enable healthcare professionals to provide accurate information concerning the side effect profile of PPIs and educate patients on informed decision-making regarding PPI therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.